Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Piribedil tinnitus crossover study

Also known as: Piribedil

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Not applicable

Status

Completed

Target Gene

—

Route / Mode

Oral

Confidence

85%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Brazil

Population

adult, tinnitus

Trial IDs

Mechanism

Historical randomized crossover tinnitus study of piribedil therapy guided by otoacoustic emissions and electrocochleography.

Indications

Tinnitus

Notes

Registry-verified historical academic trial. No current product-development or industry-sponsored hearing-loss program was verified from this registry record.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...

IDs: NCT00591994

Open

Key Events

2006-11

Piribedil tinnitus treatment study started

Clinical Trials (1)

NCT00591994

Data Checks

institution-led-studyregistry-only-evidencehistorical-studynot-confirmed-current-product

Related Programs

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

AC102 by AudioCure Pharma

Company: AudioCure Pharma · Small Molecule · Phase 2

SPI-1005 by Sound Pharmaceuticals

Company: Sound Pharmaceuticals · Small Molecule · Phase 3

ACOU085 by Acousia Therapeutics

Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2

CIL001 (Paliroden) by Cilcare

Company: Cilcare SAS · Small Molecule · Phase 1/2